New drug could ease stubborn shoulder pain

NCT ID NCT05569174

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether secukinumab, an anti-inflammatory drug, can reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon pain) that didn't get better with standard treatments. 62 participants received either the drug or a placebo for 12 weeks. The main goal was to see if shoulder-related quality of life improved after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (a drug that targets inflammation)
What this could lead to: If it works, this could provide a new treatment option for people with stubborn shoulder tendon pain that hasn't improved with standard care.
What could go wrong: This is a small, early-phase trial with only 62 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease of the tendon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TENDINOPATHY

Contacts and locations

Locations

Novartis Investigative Site

Karlsruhe, Baden-Wurttemberg, 76133, Germany
Novartis Investigative Site

Munich, Bavaria, 80809, Germany
Novartis Investigative Site

Hanover, Lower Saxony, 30159, Germany
Novartis Investigative Site

Halle, Saxony-Anhalt, 06120, Germany
Novartis Investigative Site

Bad Doberan, 18209, Germany
Novartis Investigative Site

Berlin, 10787, Germany
Novartis Investigative Site

Berlin, 12627, Germany
Novartis Investigative Site

Cottbus, 03042, Germany
Novartis Investigative Site

Dresden, 01069, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Frankfurt am Main, 60313, Germany
Novartis Investigative Site

Gladbeck, 45968, Germany
Novartis Investigative Site

Hamburg, 20095, Germany
Novartis Investigative Site

Hamburg, 20149, Germany
Novartis Investigative Site

Hamburg, 22415, Germany
Novartis Investigative Site

Heinsberg, 52525, Germany
Novartis Investigative Site

Herne, 44649, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Schönebeck, 39218, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.